{"id":"cggv:402ff7db-2e09-4e76-9284-1e7c4ae84fb3v1.0","type":"EvidenceStrengthAssertion","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"cggv:402ff7db-2e09-4e76-9284-1e7c4ae84fb3_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10080","date":"2023-01-07T12:00:00.000Z","role":"Approver"},{"id":"cggv:402ff7db-2e09-4e76-9284-1e7c4ae84fb3_publish_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10080","date":"2023-01-07T11:46:14.093Z","role":"Publisher"}],"evidence":[{"id":"cggv:402ff7db-2e09-4e76-9284-1e7c4ae84fb3_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:402ff7db-2e09-4e76-9284-1e7c4ae84fb3_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:eaa1df8d-2095-439f-9995-938092b706e5","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:45f2423d-aead-4854-8762-7bef427918b4","type":"Finding","demonstrates":{"id":"cg:GeneExpressionA"},"dc:description":"To establish a resource database and associated tissue bank to study the relationship between genetic variation and gene expression in human tissues, donors of any racial and ethnic group and sex who are age 21–70 in whom biospecimen collection can start within 24 hours of death were eligible. Medical exclusionary criteria were: human immunodeficiency virus (HIV) infection or high-risk behaviors, viral hepatitis, metastatic cancer, chemotherapy or radiation therapy for any condition within the past 2 years, whole blood transfusion in past 48 hours, or body mass index ≥ 35 or ≤18.5. Each BSS collects, where feasible, aliquots from many pre-designated tissue sites and organs, including the brain of deceased donors who were not on a ventilator for the 24 hours prior to death. \nA dedicated team of pathologists reviews slides from all tissue specimens to verify the organ source and to characterize both general pathological characteristics, such as autolysis, as well as organ-specific pathological states and inflammation. \nNormal expression of TCF3 has been detected in EBV-transformed cells. \n","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/23715323","type":"dc:BibliographicResource","dc:abstract":"Genome-wide association studies have identified thousands of loci for common diseases, but, for the majority of these, the mechanisms underlying disease susceptibility remain unknown. Most associated variants are not correlated with protein-coding changes, suggesting that polymorphisms in regulatory regions probably contribute to many disease phenotypes. Here we describe the Genotype-Tissue Expression (GTEx) project, which will establish a resource database and associated tissue bank for the scientific community to study the relationship between genetic variation and gene expression in human tissues.","dc:creator":"GTEx Consortium","dc:date":"2013","dc:title":"The Genotype-Tissue Expression (GTEx) project."},"rdfs:label":"The Genotype-Tissue Expression (GTEx) project"}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5},{"id":"cggv:402ff7db-2e09-4e76-9284-1e7c4ae84fb3_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:3220223a-3a71-4155-ac94-b10d895c8641","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:37c5b205-5f65-47d9-91a0-b8d77d23a1b0","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"Arrest of early B cell development and agammaglobulinemia or profound hypogammaglobulinemia are the main characteristics of patients carrying TCF3 mutation. This mouse model gives evidence of arrested B cell differentiation at an early stage and \nfailure to rearrange  immunoglobulin gene segments. Heterozygote animals also show decreased numbers of both pro-B and mature B cells. \n\n\n","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/8001125","type":"dc:BibliographicResource","dc:abstract":"E12 and E47 are two helix-loop-helix transcription factors that arise by alternative splicing of the E2A gene. Both have been implicated in the regulation of immunoglobulin gene expression. We have now generated E2A (-/-) mice by gene targeting. E2A-null mutant mice fail to generate mature B cells. The arrest of B cell development occurs at an early stage, since no immunoglobulin DJ rearrangements can be detected in homozygous mutant mice. While immunoglobulin germline I mu RAG-1, mb-1, CD19, and lambda 5 transcripts are dramatically reduced in fetal livers of E2A (-/-) mice, B29 and mu degrees transcripts are present, but at lower levels. In addition, we show that Pax-5 transcripts are significantly reduced in fetal livers of E2A (-/-) mice. These data suggest a crucial role for E2A products as central regulators in early B cell differentiation.","dc:creator":"Bain G","dc:date":"1994","dc:title":"E2A proteins are required for proper B cell development and initiation of immunoglobulin gene rearrangements."},"rdfs:label":"Consequences of E2A null mutation in mice"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"cggv:1aeef7bf-c6d3-47d7-b219-5a52eb899322","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:611620c1-f967-4020-a2fb-6778671235bf","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"Arrest in B cell development with resultant agammaglobulinemia and early onset infections is well observed in patients carrying TCF3 mutations. The model system showed that E47 is essential for developmental progression at the prepro–B cell stage.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/19752184","type":"dc:BibliographicResource","dc:abstract":"The E2A gene products, E12 and E47, are critical regulators of B cell development. However, it remains elusive whether E12 and E47 have overlapping and/or distinct functions during B lymphopoiesis. We have generated mice deficient for either E12 or E47 and examined their roles in B cell maturation. We show that E47 is essential for developmental progression at the prepro-B cell stage, whereas E12 is dispensable for early B cell development, commitment, and maintenance. In contrast, both E12 and E47 play critical roles in pre-B and immature B cells to promote immunoglobulin lambda (Ig lambda) germline transcription as well as Ig lambda VJ gene rearrangement. Furthermore, we show that E12 as well as E47 is required to promote receptor editing upon exposure to self-antigen. We demonstrate that increasing levels of E12 and E47 act to induce Ig lambda germline transcription, promote trimethylated lysine 4 on histone 3 (H3) as well as H3 acetylation across the J lambda region, and activate Ig lambda VJ gene rearrangement. We propose that in the pre-B and immature B cell compartments, gradients of E12 and E47 activities are established to mechanistically regulate the sequential rearrangement of the Ig light chain genes.","dc:creator":"Beck K","dc:date":"2009","dc:title":"Distinct roles for E12 and E47 in B cell specification and the sequential rearrangement of immunoglobulin light chain loci."},"rdfs:label":"Arrest in B cell development in E47−/− mice"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":4.5},{"id":"cggv:402ff7db-2e09-4e76-9284-1e7c4ae84fb3_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:7bcf1b3d-e8e0-42d1-bf3d-c2c43a25f3fc_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:7bcf1b3d-e8e0-42d1-bf3d-c2c43a25f3fc","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":11,"allele":{"id":"cggv:913942f9-9630-456d-a8f5-647171fcf7ea","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003200.5(TCF3):c.1823-508G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10576120"}},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"A complete absence of CD19 and CD20-positive B cells","phenotypes":["obo:HP_0002090","obo:HP_0011919","obo:HP_0004432"],"sex":"Female","variant":{"id":"cggv:355e2644-d3a0-4efd-ad46-eea67615d3f2_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:913942f9-9630-456d-a8f5-647171fcf7ea"},"alleleOrigin":{"id":"obo:GENO_0000880"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:MonoallelicHeterozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/33905048","type":"dc:BibliographicResource","dc:creator":"Al Sheikh E","dc:date":"2021","dc:title":"TCF3 Dominant Negative Variant Causes an Early Block in B-Lymphopoiesis and Agammaglobulinemia."}},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"rdfs:label":"Al Sheikh_P1"},{"id":"cggv:355e2644-d3a0-4efd-ad46-eea67615d3f2","type":"obo:SEPIO_0004097","calculatedScore":2.5,"direction":"Supports","evidence":[{"id":"cggv:355e2644-d3a0-4efd-ad46-eea67615d3f2_variant_evidence_item"},{"id":"cggv:355e2644-d3a0-4efd-ad46-eea67615d3f2_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Nuclear extracts from HEK-293 cells transfected with an empty vector or expression vectors producing wild-type E12 or E47 or E555K E47 were incubated with the μE5 probe in EMSAs. Wild-type E12 and E47 provided strong signals, but the mutant E47 gave a signal that was consistently less than 5% of that seen for wild-type E47. \n"}],"strengthScore":2.5,"dc:description":"The variant is a de novo heterozygous c.1663G>A transition in exon 18b, which is specific to the E47 isoform of the TCF3 gene, resulting in a glu555-to-lys (E555K) substitution at a highly conserved residue in the DNA-binding domain. In vitro functional expression studies and studies of patient cells showed that the mutant E47 protein does not perform proper DNA binding and acted in a dominant-negative manner when coexpressed with wildtype. Since paternity was confirmed, we gave the full score for the variant detected in the proband."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:0087aa47-05c7-4f83-b396-74421f8dc1b6_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:0087aa47-05c7-4f83-b396-74421f8dc1b6","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":4,"allele":{"id":"cggv:913942f9-9630-456d-a8f5-647171fcf7ea"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Early onset infections, recurrent otitis and arthritis.  profound hypogammaglobulinemia. <3% CD19+ on multiple occasions.","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"cggv:4130e87a-3b9e-44c0-ab32-63afa7cbcb70_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:913942f9-9630-456d-a8f5-647171fcf7ea"},"alleleOrigin":{"id":"obo:GENO_0000880"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:MonoallelicHeterozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/24216514","type":"dc:BibliographicResource","dc:abstract":"Approximately 90% of patients with isolated agammaglobulinemia and failure of B cell development have mutations in genes required for signaling through the pre–B cell and B cell receptors. The nature of the gene defect in the majority of remaining patients is unknown. We recently identified 4 patients with agammaglobulinemia and markedly decreased numbers of peripheral B cells. The B cells that could be detected had an unusual phenotype characterized by the increased expression of CD19 but the absence of a B cell receptor. Genetic studies demonstrated that all 4 patients had the exact same de novo mutation in the broadly expressed transcription factor E47. The mutant protein (E555K) was stable in patient-derived EBV-transformed cell lines and cell lines transfected with expression vectors. E555K in the transfected cells localized normally to the nucleus and resulted in a dominant negative effect when bound to DNA as a homodimer with wild-type E47. Mutant E47 did permit DNA binding by a tissue-specific heterodimeric DNA-binding partner, myogenic differentiation 1 (MYOD). These findings document a mutational hot-spot in E47 and represent an autosomal dominant form of agammaglobulinemia. Further, they indicate that E47 plays a critical role in enforcing the block in development of B cell precursors that lack functional antigen receptors.","dc:creator":"Boisson B","dc:date":"2013","dc:title":"A recurrent dominant negative E47 mutation causes agammaglobulinemia and BCR(-) B cells."}},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"rdfs:label":"Boisson_4"},{"id":"cggv:4130e87a-3b9e-44c0-ab32-63afa7cbcb70","type":"obo:SEPIO_0004097","calculatedScore":2.5,"direction":"Supports","evidence":[{"id":"cggv:4130e87a-3b9e-44c0-ab32-63afa7cbcb70_variant_evidence_item"},{"id":"cggv:4130e87a-3b9e-44c0-ab32-63afa7cbcb70_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":" Nuclear extracts from HEK-293 cells transfected with an empty vector or expression vectors producing wild-type E12 or E47 or E555K E47 were incubated with the μE5 probe in EMSAs. Wild-type E12 and E47 provided strong signals, but the mutant E47 gave a signal that was consistently less than 5% of that seen for wild-type E47 \n"}],"strengthScore":1,"dc:description":"The variant is a de novo heterozygous c.1663G>A transition in exon 18b, which is specific to the E47 isoform of the TCF3 gene, resulting in a glu555-to-lys (E555K) substitution at a highly conserved residue in the DNA-binding domain. In vitro functional expression studies and studies of patient cells showed that the mutant E47 protein does not perform proper DNA binding and acted in a dominant-negative manner when coexpressed with wildtype. Downscoring for lack of paternity confirmation and functional data from the patient cells."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:1a92d957-2eb3-41df-91fc-bea0a7145506_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:1a92d957-2eb3-41df-91fc-bea0a7145506","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":10,"allele":{"id":"cggv:913942f9-9630-456d-a8f5-647171fcf7ea"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Early onset of infections, recurrent otitis. profound hypogammaglobulinemia. <3% CD19+ cells in the circulation on multiple occasions.","phenotypes":"obo:HP_0032022","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"cggv:08db4f4c-d9fa-4a09-b868-ebf5ad929c18_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:913942f9-9630-456d-a8f5-647171fcf7ea"},"alleleOrigin":{"id":"obo:GENO_0000880"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:MonoallelicHeterozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24216514"},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"rdfs:label":"Boisson_2"},{"id":"cggv:08db4f4c-d9fa-4a09-b868-ebf5ad929c18","type":"obo:SEPIO_0004097","calculatedScore":2.5,"direction":"Supports","evidence":[{"id":"cggv:08db4f4c-d9fa-4a09-b868-ebf5ad929c18_variant_evidence_item"},{"id":"cggv:08db4f4c-d9fa-4a09-b868-ebf5ad929c18_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Nuclear extracts from HEK-293 cells transfected with an empty vector or expression vectors producing wild-type E12 or E47 or E555K E47 were incubated with the μE5 probe in EMSAs. Wild-type E12 and E47 provided strong signals, but the mutant E47 gave a signal that was consistently less than 5% of that seen for wild-type E47.\n"}],"strengthScore":1.5,"dc:description":"The variant is a de novo heterozygous c.1663G>A transition in exon 18b, which is specific to the E47 isoform of the TCF3 gene, resulting in a glu555-to-lys (E555K) substitution at a highly conserved residue in the DNA-binding domain. In vitro functional expression studies and studies of patient cells showed that the mutant E47 protein does not perform proper DNA binding and acted in a dominant-negative manner when coexpressed with wildtype. Downscoring for lack of paternity confirmation."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:ccd1445a-cf62-416a-a086-3f187f56b2ce_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:ccd1445a-cf62-416a-a086-3f187f56b2ce","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":9,"allele":{"id":"cggv:913942f9-9630-456d-a8f5-647171fcf7ea"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Early onset of infections, pneumococcal meningitis. profound hypogammaglobulinemia. <3% CD19+ on multiple occasions.","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"cggv:90ddf987-f73e-4c25-8fd9-a5e105dc41dc_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:913942f9-9630-456d-a8f5-647171fcf7ea"},"alleleOrigin":{"id":"obo:GENO_0000880"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:MonoallelicHeterozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24216514"},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"rdfs:label":"Boisson_1"},{"id":"cggv:90ddf987-f73e-4c25-8fd9-a5e105dc41dc","type":"obo:SEPIO_0004097","calculatedScore":2.5,"direction":"Supports","evidence":[{"id":"cggv:90ddf987-f73e-4c25-8fd9-a5e105dc41dc_variant_evidence_item"},{"id":"cggv:90ddf987-f73e-4c25-8fd9-a5e105dc41dc_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Nuclear extracts from HEK-293 cells transfected with an empty vector or expression vectors producing wild-type E12 or E47 or E555K E47 were incubated with the μE5 probe in EMSAs. Wild-type E12 and E47 provided strong signals, but the mutant E47 gave a signal that was consistently less than 5% of that seen for wild-type E47 \n"}],"strengthScore":2.5,"dc:description":"The variant is a de novo heterozygous c.1663G>A transition in exon 18b, which is specific to the E47 isoform of the TCF3 gene, resulting in a glu555-to-lys (E555K) substitution at a highly conserved residue in the DNA-binding domain. In vitro functional expression studies and studies of patient cells showed that the mutant E47 protein does not perform proper DNA binding and acted in a dominant-negative manner when coexpressed with wildtype. "}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:5f00e27c-c3ab-42ac-88da-6a87aa0d292f_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:5f00e27c-c3ab-42ac-88da-6a87aa0d292f","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":24,"allele":{"id":"cggv:913942f9-9630-456d-a8f5-647171fcf7ea"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Vaccine associated polio. Early onset infections. Profound hypogammaglobulinemia, <3% CD19+ cells in the circulation on multiple occasions. ","phenotypes":"obo:HP_0002240","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"cggv:b1fa1ee5-8f05-49ab-b1b1-ab16613e830e_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:913942f9-9630-456d-a8f5-647171fcf7ea"},"alleleOrigin":{"id":"obo:GENO_0000880"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:MonoallelicHeterozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24216514"},"zygosity":{"id":"cg:MonoallelicHeterozygous"},"rdfs:label":"Boisson_3"},{"id":"cggv:b1fa1ee5-8f05-49ab-b1b1-ab16613e830e","type":"obo:SEPIO_0004097","calculatedScore":2.5,"direction":"Supports","evidence":[{"id":"cggv:b1fa1ee5-8f05-49ab-b1b1-ab16613e830e_variant_evidence_item"},{"id":"cggv:b1fa1ee5-8f05-49ab-b1b1-ab16613e830e_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Nuclear extracts from HEK-293 cells transfected with an empty vector or expression vectors producing wild-type E12 or E47 or E555K E47 were incubated with the μE5 probe in EMSAs. Wild-type E12 and E47 provided strong signals, but the mutant E47 gave a signal that was consistently less than 5% of that seen for wild-type E47 \n"}],"strengthScore":1.5,"dc:description":"The variant is a de novo heterozygous c.1663G>A transition in exon 18b, which is specific to the E47 isoform of the TCF3 gene, resulting in a glu555-to-lys (E555K) substitution at a highly conserved residue in the DNA-binding domain. In vitro functional expression studies and studies of patient cells showed that the mutant E47 protein does not perform proper DNA binding and acted in a dominant-negative manner when coexpressed with wildtype. Downscoring for lack of paternity confirmation."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":9}],"evidenceStrength":"Definitive","sequence":5729,"specifiedBy":"GeneValidityCriteria9","strengthScore":13.5,"subject":{"id":"cggv:0c4e3b74-9fc3-465f-b7cc-f5e7ebb8a9a5","type":"GeneValidityProposition","disease":"obo:MONDO_0011096","gene":"hgnc:11633","modeOfInheritance":"obo:HP_0032113"},"version":"1.0","dc:description":"*TCF3* was first reported in relation to autosomal agammaglobulinemia in 2013 ( PMID: 24216514). *TCF3* encodes the 2 broadly expressed founding members of the basic helix-loop-helix (bHLH) family of transcription factors, E12 and E47. They are identical except for their bHLH domains, which are provided by alternatively spliced exons. E12 and E47 are essential in the differentiation process of common lymphoid progenitors into B-lineage cells and are key regulators of B-cell development. Both autosomal dominant and autosomal recessive inheritance have been reported. Due to lack of distinctive features in the small number of patients reported and the experimental evidence that supports autosomal recessive and autosomal dominant disease, the antibody deficiency GCEP came to the decision of lumping both modes of inheritance at this stage.\n\nA de-novo mutation that results in a dominant negative effect, has been reported in 5 unrelated individuals in 2 publications (PMIDs: 24216514 and 33905048). A heterozygous frameshift has been detected in a proband with reduced switched memory cells and recurrent infections (PMID: 29114388). Biallelic TCF3 mutations (a large deletion and a nonsense) have been reported in 3 patients (PMIDs: 30063982 and Barbouche, et al., 2016)\n\nExperimental evidence includes expression in relevant tissues and animal model. B cells of E2A (-I-) mice are arrested at an early stage of B cell differentiation. Heterozygote animals also showed decreased numbers of both pro-B and mature B cells (PMID: 8001124).\nIn summary *TCF3* is definitively associated with autosomal agammaglobulinemia. This has been repeatedly demonstrated in both the research and clinical diagnostic settings and has been upheld over time.\nGene Clinical Validity Standard Operating Procedures (SOP) -SOP8\n\n","dc:isVersionOf":{"id":"cggv:402ff7db-2e09-4e76-9284-1e7c4ae84fb3"},"@context":{"@vocab":"http://dataexchange.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"http://dataexchange.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"http://dataexchange.clinicalgenome.org/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"}}}